Ticlopidine hydrochloride use and threatened stroke

Area of Science:

• Pharmacology
• Neurology
• Clinical Medicine

Background:

• Ticlopidine hydrochloride is an antiplatelet agent with established antithrombotic efficacy.
• Its clinical availability in the US presents a comparison with aspirin, another antiplatelet agent.
• The comparative value of ticlopidine versus aspirin is a significant clinical consideration.

Purpose of the Study:

• To evaluate the relative benefits, risks, and costs of ticlopidine compared to aspirin for preventing thrombotic events.
• To identify specific patient populations for whom ticlopidine may be recommended over aspirin.
• To outline criteria for the appropriate use of ticlopidine in cerebrovascular conditions.

Main Methods:

• Comparative analysis of clinical efficacy data for ticlopidine and aspirin.
• Assessment of toxicity profiles and cost-effectiveness.
• Review of existing data on cerebrovascular conditions and antithrombotic therapies.

Main Results:

• Ticlopidine demonstrates greater efficacy than aspirin in preventing stroke in certain populations.
• Ticlopidine is associated with higher costs and potential toxicity compared to aspirin.
• Specific indications for ticlopidine include aspirin-intolerant patients with threatened stroke and those with persistent cerebral ischemic symptoms despite aspirin therapy.

Conclusions:

• Ticlopidine is recommended for specific patient groups, including those intolerant to aspirin or experiencing stroke despite aspirin therapy.
• Its use in other cerebrovascular conditions is not strongly supported by current data.
• The decision to use ticlopidine involves a complex risk-benefit-cost analysis and necessitates feasible laboratory monitoring for neutropenia.